Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM6A | O15550 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20386661 | 0.84 | KDM4E (0.57) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL10480769 | 0.83 | KDM4E (0.42) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL8716751 | 0.83 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL878561 | 0.81 | KDM4E (0.40) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL2837599 | 0.80 | KDM4E (0.53) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL5525055 | 0.78 | KDM4E (0.62) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL3083137 | 0.77 | KDM4E (0.61) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL13003558 | 0.77 | KDM4E (0.60) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4394165 | 0.75 | KDM4E (0.58) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL9513592 | 0.75 | APP (0.61) | KDM4ETP53CYP2D6HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50230-E1 | Method of treatment of hypoxia inducible factor (HIF)-related conditions | GRIFOLS WORLDWIDE OPERATIONS LIMITED (IE) | 2024-12-10 | — | — | US | claimed |
| WO-1989009211-A1 | PROCESS FOR PRODUCING PYRID-4-ONES | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-05 | — | — | WO | claimed |
| EP-0335745-A1 | Process for producing pyrid-4-ones | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-04 | — | — | EP | claimed |
| US-RE50230-E1 | Method of treatment of hypoxia inducible factor (HIF)-related conditions | GRIFOLS WORLDWIDE OPERATIONS LIMITED (IE) | 2024-12-10 | — | — | US | disclosed |
| US-11826353-B2 | Method and system for treating cancer | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2023-11-28 | — | — | US | disclosed |
| US-11759453-B2 | SHMT inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-03-30 | — | — | US | disclosed |
| US-11369588-B2 | NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190336583-A1 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | LA JOLLA PHARMACEUTICAL COMPANY | 2019-11-07 | — | — | US | disclosed |
| WO-2018136636-A1 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-2665493-B1 | MRI MARKERS, DELIVERY AND EXTRACTION SYSTEMS, AND METHODS OF MANUFACTURE AND USE THEREOF | UNIV TEXAS (US) | 2018-03-21 | — | — | EP | disclosed |
| CN-1252079-C | Substance with physiological activity, its preparation method and application | AMINO UP CHEMICAL CO LTD (JP) | 2006-04-19 | — | — | CN | disclosed |
| US-20050143341-A1 | Novel substance having physiological property, method for producing the same and uses thereof | AMINO UP CHEMICAL CO., LTD. | 2005-06-30 | — | — | US | disclosed |
| US-6831067-B2 | Glucosides containing isomaltol as an aglycon produced reacting a basidiomycete culture solution with the reaction product of rice bran extracts and an enzyme | AMINO UP CHEMICAL CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| CN-1422277-A | Substance with physiological activity, its preparation method and application | AMINO UP CHEMICAL CO LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
| EP-1298137-A1 | NOVEL SUBSTANCE HAVING PHYSIOLOGICAL ACTIVITY, PROCESS FOR PRODUCING THE SAME, AND USE | AMINO UP CHEMICAL CO. LTD. (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20030045483-A1 | Novel substance having physiological activity, process for producing the same, and use | Amino Up Co., Ltd. (JP) | 2003-03-06 | — | — | US | disclosed |
| US-5336482-A | Diagnostic scintigraphic imaging | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-08-09 | — | — | US | disclosed |
| WO-1989009211-A1 | PROCESS FOR PRODUCING PYRID-4-ONES | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-05 | — | — | WO | disclosed |
| EP-0335745-A1 | Process for producing pyrid-4-ones | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759453-B2 | SHMT inhibitors | SHMT1, SHMT2, BHMT | KDM4E 229/4885TP53 103/4885CYP2D6 2358/4885 |
| US-11369588-B2 | NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease | MTHFD1, DPYD, MTHFD2 | KDM4E 2103/4885TP53 1993/4885CYP2D6 715/4885 |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | SHMT2, PC, ME2 | KDM4E 3084/4885TP53 2252/4885CYP2D6 3232/4885 |
| US-20030045483-A1 | Novel substance having physiological activity, process for producing the same, and use | UGGT1, IGFBP1, MGAM | KDM4E 4645/4885TP53 4284/4885CYP2D6 2338/4885 |
| US-20050143341-A1 | Novel substance having physiological property, method for producing the same and uses thereof | UGGT1, MGAM, IL6 | KDM4E 4631/4885TP53 3685/4885CYP2D6 1469/4885 |
| US-20190336583-A1 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | HAMP, FTH1, SLC40A1 | KDM4E 4672/4885TP53 2331/4885CYP2D6 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.